← Back to Search

Virus Therapy

MBI vs. MRI for Detecting Breast Cancer

N/A

Recruiting

Led By Hannah L Chung

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is comparing the effectiveness of two different methods of detecting breast cancer in high-risk women.

Who is the study for?

This trial is for women aged 18 or older at high risk for breast cancer, which includes those with a lifetime risk over 20%, certain cell changes like lobular neoplasia or atypical ductal hyperplasia, or known genetic mutations. Pregnant women can't participate due to the use of radioactive tracers and gadolinium.Check my eligibility

What is being tested?

The study is comparing two imaging techniques: Molecular Breast Imaging (MBI) using Tc99m sestamibi and Magnetic Resonance Imaging (MRI). It aims to see how well MBI performs in detecting breast cancer compared to MRI, especially considering tumor size, type, and location.See study design

What are the potential side effects?

Potential side effects from MBI may include discomfort from the injection of the radioactive tracer. For MRI, there might be reactions to gadolinium contrast such as nausea or allergic reactions; however individual experiences vary.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To establish the diagnostic performance of Molecular Breast Imaging (MBI) to breast Magnetic Resonance Imaging (MRI) in women who are at high risk of developing breast cancer

Trial Design

1Treatment groups

Experimental Treatment

Group I: Tc99m sestamibiExperimental Treatment1 Intervention

MBI uses an injection of a small amount of radioactive material called technetium99m (Tc99m) sestamibi

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,974 Previous Clinical Trials

1,789,096 Total Patients Enrolled

147 Trials studying Breast Cancer

62,986 Patients Enrolled for Breast Cancer

Hannah L ChungPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Tc99m sestamibi (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05042687 — N/A

Breast Cancer Research Study Groups: Tc99m sestamibi

Breast Cancer Clinical Trial 2023: Tc99m sestamibi Highlights & Side Effects. Trial Name: NCT05042687 — N/A

Tc99m sestamibi (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05042687 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have any prior experiments utilized Tc99m sestamibi?

"Presently, 3 clinical trials related to Tc99m sestamibi are ongoing. However, none have progressed to Phase Three yet. Most of the research is conducted in Houston, Texas but 8 other sites around America are also running studies with this treatment."

Answered by AI

How many participants are taking part in this experiment?

"Affirmative. The information found on clinicaltrials.gov states that this medical trial is currently recruiting individuals, having first been posted in December 2021 and last updated November 2022. 300 participants are being sought from a single centre of study."

Answered by AI

Is this experiment presently open to participants?

"Per information on clinicaltrials.gov, recruitment for this study is open to qualified candidates. The trial was initially posted in December 2021 and underwent its last update in November 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

2021. "Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05042687.